EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Priscilla K Brastianos iD, Erin Twohy, Susan Geyer, Elizabeth R Gerstner, Timothy J Kaufmann, Shervin Tabrizi, Brian Kabat, Julia Thierauf, Michael W Ruff, Daniela A Bota, David A Reardon, Adam L Cohen und 16 weitere

New England Journal of Medicine · 13.07.2023 · 389 (2) · 118-126

DOI: 10.1056/nejmoa2213329 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 13.07.2023. Verfasst von Priscilla K Brastianos und 27 weiteren Autor:innen. Beteiligte Einrichtung: From Massachusetts General Hospital Cancer Center, Harvard Medical School (P.K.B., E.R.G., S.T., J.T., A.J.I., W.T.C., D.P.C., H.A.S., F.G.B.), Dana-…. Hauptthemen laut MEDLINE: Craniopharyngioma, Pituitary Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 141-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genentech, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% of papillary craniopharyngiomas carry BRAF V600E mutations, but data are lacking with regard to the safety and efficacy of BRAF-MEK inhibition in patients with papillary craniopharyngiomas who have not undergone previous radiation therapy. METHODS: Eligible patients who had papillary craniopharyngiomas that tested positive for BRAF mutations, had not undergone radiation therapy previously, and had measurable disease received the BRAF-MEK inhibitor combination vemurafenib-cobimetinib in 28-day cycles. The primary end point of this single-group, phase 2 study was objective response at 4 months as determined with the use of centrally determined volumetric data. RESULTS: Of the 16 patients in the study, 15 (94%; 95% confidence interval [CI], 70 to 100) had a durable objective partial response or better to therapy. The median reduction in the volume of the tumor was 91% (range, 68 to 99). The median follow-up was 22 months (95% CI, 19 to 30) and the median number of treatment cycles was 8. Progression-free survival was 87% (95% CI, 57 to 98) at 12 months and 58% (95% CI, 10 to 89) at 24 months. Three patients had disease progression during follow-up after therapy had been discontinued; none have died. The sole patient who did not have a response stopped treatment after 8 days owing to toxic effects. Grade 3 adverse events that were at least possibly related to treatment occurred in 12 patients, including rash in 6 patients. In 2 patients, grade 4 adverse events (hyperglycemia in 1 patient and increased creatine kinase levels in 1 patient) were reported; 3 patients discontinued treatment owing to adverse events. CONCLUSIONS: In this small, single-group study involving patients with papillary craniopharyngiomas, 15 of 16 patients had a partial response or better to the BRAF-MEK inhibitor combination vemurafenib-cobimetinib. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT03224767.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CraniopharyngiomaPituitary NeoplasmsAntineoplastic AgentsHumansDisease ProgressionMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins B-rafVemurafenibRemission InductionAzetidinesPiperidines

Substanzen

Mitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins B-rafVemurafenibAntineoplastic AgentsBRAF protein, humancobimetinibAzetidinesPiperidines

Autor:innen und Institutionen

  • From Massachusetts General Hospital Cancer Center, Harvard Medical School (P.K.B., E.R.G., S.T., J.T., A.J.I., W.T.C., D.P.C., H.A.S., F.G.B.), Dana-Farber Cancer Institute (D.A.R.), and Brigham and Women's Hospital, Ha…

ORCID-Profile: Priscilla K Brastianos

Förderung

  • NCI NIH HHS
  • Genentech
  • National Cancer Institute

Zitieren

APA

Brastianos, P. K., Twohy, E., Geyer, S., Gerstner, E. R., Kaufmann, T. J., Tabrizi, S., Kabat, B., Thierauf, J., Ruff, M. W., Bota, D. A., Reardon, D. A., Cohen, A. L., De La Fuente, M. I., Lesser, G. J., Campian, J., Agarwalla, P. K., Kumthekar, P., Mann, B., Vora, S., …, & Galanis, E. (2023). BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. New England Journal of Medicine, 389(2), 118-126. https://doi.org/10.1056/nejmoa2213329

Vancouver

Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, et al. BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. New England Journal of Medicine. 2023;389(2):118-126. doi:10.1056/nejmoa2213329

BibTeX
@article{Brastianos2023,
  author = {Brastianos, Priscilla K and Twohy, Erin and Geyer, Susan and Gerstner, Elizabeth R and Kaufmann, Timothy J and Tabrizi, Shervin and Kabat, Brian and Thierauf, Julia and Ruff, Michael W and Bota, Daniela A and Reardon, David A and Cohen, Adam L and De La Fuente, Macarena I and Lesser, Glenn J and Campian, Jian and Agarwalla, Pankaj K and Kumthekar, Priya and Mann, Bhupinder and Vora, Shivangi and Knopp, Michael and Iafrate, A John and Curry, William T and Cahill, Daniel P and Shih, Helen A and Brown, Paul D and Santagata, Sandro and Barker, Fred G and Galanis, Evanthia},
  title = {BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {2},
  pages = {118--126},
  doi = {10.1056/nejmoa2213329}
}
Kostenlos starten →